



29 SEPT – 2 OCT 2022
ICC BELFAST
NORTHERN IRELAND, UK

PROGRAMME

DAY 1 Thursday 29 September		Hall 1A
0900 - 1600	Registration Bag drop Register early: RSV2022 delegates are welcome to join OPTIONS XI DAY 4 sessions at the ICC	
1700 - 1710	Welcome Address: Chair, Prof. Ultan F. Power Queen's University Belfast	
1710 - 1730	Opening Keynote José Antonio Melero Early Career Investigator Award The Past, Present and Future with RSV Dr Vahid Salimi Tehran University of Medical Sciences, Iran	
1730 - 1900	SESSION 1 – RSV Molecular Biology Chairs: Prof. Jason McClellan, The University of Texas at Austin, USA Dr. Olivier Touzelet, Queen's University Belfast, UK	
1730 - 1800	Keynote: Structure and Assembly of RSV Dr Swetha Vijakrishnan University of Glasgow, UK	
1800 - 1815	RSV Viral Factories are Druggable Multiphasic Biocondensates Marie-Ann Rameix-Welti Université Paris-Saclay, Université de Versaille, France [ARNI0003]	
1815 - 1830	Elucidating the Role of the Pep27 Fragment in RSV Fusion Protein Function and Stability Hadley Neal University of Kentucky, USA [ARNI0119]	
1830 - 1845	Respiratory Syncytial Virus NS1 Protein Targets the Transactivator Binding Domain of MED25 Monika Bajorek INRAE, France [ARNI0009]	
1845 - 1900	Single-Molecule Imaging Unravels Real-time Transcription and Replication Dynamics of RSV Dhanushika Ratnayake Hubrecht Institute, Utrecht, Netherlands [ARNI0136]	
1900 - late	Welcome Reception	
		End of Day 1

DAY 2 **Friday 30 September**

Hall 1A

0900 - 1030

SESSION 2 – RSV Immunology – Pre-Clinical

Chairs: Prof. Barney Graham, Morehouse School of Medicine, USA

Dr. Jeremy Anderson, Murdoch Children's Research Institute, Australia

0900 - 0930

Keynote: A Novel Microbiota-host Interaction to Explain How Poor Maternal Diet Predisposes to Severe Viral Bronchiolitis

A/Prof. Simon Phipps | QIMR Berghofer, QLD, Australia

0930 - 0945

Comparing the Cell-specific Innate Immune Response to RSV Between Preterm and Term Infants

Yan Yung Ng | Murdoch Children's Research Institute, Royal Children's Hospital, Australia [ARNI0221]

0945 - 1000

Presence of Neutrophils in the Lungs Prior to Infection with Respiratory Viruses Influences Disease Severity in Mice

Amber Owen | Imperial College London, UK

[ARNI0127]

1000 - 1015

Advanced Modeling of RSV Infection in Neonatal Lambs

Sarhad Alnajarr | Lambcure LLC, Iran

[ARNI0029]

1015 - 1030

Trans-epithelial Migration is Essential for Neutrophil Activation in the Airway During RSV Infection

Elisabeth Robinson | UCL Great Ormond Street Institute of Child Health, London, UK

[ARNI0150]

1030 - 1100

Refreshment break - Posters

1100-1230

SESSION 3 – RSV Vaccines and Monoclonals

Chairs: Dr. Simon Drysdale, St. George's Hospital London, UK

Ms. Valentina Eberlein, Fraunhofer Institute for Cell Therapy and Immunology, Germany

1100 - 1130

Keynote: Progress in the Prevention of RSV Disease: a Whirlwind Tour

Prof. Ruth Karron | Johns Hopkins University, USA

1130 - 1145

Safety and Immunogenicity of mRNA-1345, an mRNA-Based Vaccine Against RSV in Older Adults through 6 Month Follow-up

Sonia Stoszek | Moderna, Inc., MA, USA

[ARNI0055]

1145 - 1200

NIRSEVIMAB for the Prevention of RSV: Pooled Efficacy from Phase IIB and Phase III Trials in Preterm and Term Infants

Eric A.F.Simoës | The Children's Hospital, Aurora, USA

[ARNI0139]

1200 - 1215

Efficacy of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study of adults aged ≥65 years over 3 seasons

Ann Falsey | University of Rochester, NY, USA

[ARNI0276]

1215 - 1230	Respiratory Syncytial Virus prefusion F (RSVpreF) Vaccination: Antibody Persistence and Revaccination Edward Walsh University of Rochester, NY, USA [ARNI0243]
1230 – 1430	Lunch Hall 1 Poster Mounting
1300 – 1400	Industry symposium sponsored by Sanofi RSV Beyond RSV: Public Health Implications and Molecular Understanding of the Virus 1300-1310 Welcome, Introductions & Intro to RATTLE – Dr Simon Drysdale St George’s University of London, UK 1310-1320 Caregiver Testimony and Perspective – Christine Burlinson Parent/Caregiver 1320-1335 Understanding the Long-Term Impact and Implications of RSV – Prof. Harish Nair University of Edinburgh, UK 1335-1350 Updating Our Molecular Understanding of RSV – Dr Lindsay Broadbent University of Surrey, UK 1350-1400 Q&A and Closing - Chair & Panel
1430 - 1600	SESSION 4 – RSV Epidemiology and Disease Burden Chairs: Prof. Natasha Halasa, Vanderbilt University Medical Center, USA Ms. Sarah Hak, UMC Utrecht, The Netherlands
1430 – 1500	Keynote: An overview of the global burden of RSV Dr Meredith McMorrow CDC, USA
1500- 1515	Estimates of the National Burden of Respiratory Syncytial Virus in Kenyan Children Aged Under 5 years, 2010-2018 Patrick Munywoki Kenya Medical Research Institute, Kenya [ARNI0145]
1515 - 1530	Timing of Infection with Respiratory Syncytial Virus and Risk of Childhood Asthma Tina Hartert Vanderbilt University Medical Center, TN, USA [ARNI0172]
1530 - 1545	Hospitalization Rates and Outcomes for RSV-Associated Hospitalizations in Adults Aged 18 Years and Older in the United States During two Respiratory Seasons, October 2018 - April 2020 Fiona Havers Centers for Disease Control and Prevention, GA, USA [ARNI0099]
1545 - 1600	Early Detection and Prediction of Respiratory Syncytial Virus (RSV) Outbreaks Using Wastewater Surveillance Danielle Allen Queen's University Belfast, UK [ARNI0168]
1600 - 1630	Refreshment Break - Posters

1630 - 1650	Late Breaker session	
1630 - 1640	PK, SNA, and Efficacy to Prevent RSV MALRI from a Phase 1b/2a Study of Monoclonal Antibody Clesrovimab (MK-1654) in Infants Andrew Lee Merck & Co Inc., USA	[ARNI0268]
1640 - 1650	Nirsevimab for the Prevention of RSV Disease in Healthy Late-Preterm and Term Infants: Follow-up Through Second RSV Season Ron Dagan Ben Gurion University, Beer Sheva Israel	[ARNI0273]
1650 - 1800	SESSION 5 – Public Engagement and Question Time Moderator: Maria-Louise Connolly, BBC NI Health Correspondent Panel: Susan Adgey, Mother of a 4 year old with RSV Prof. Ann Falsey, University of Rochester, NY, USA Colm Gildernew MLA, Chair, NI Assembly Health Committee Prof. Barney Graham, Morehouse School of Medicine, USA Silke Madar, Chair of the Directors Board, European Foundation for the Care of Newborn Infants (EFCNI)	
1800 - 2000	Poster Session Wine Reception	
End of Day 2		
DAY 3 Saturday 1 October Hall 1A		
0900 - 1030	SESSION 6 – RSV Antivirals and Therapeutics Chairs: Prof. Louis Bont, University Medical Center Utrecht, The Netherlands Dr. Lindsay Broadbent, University of Surrey, UK	
0900 – 0930	Keynote: Therapeutic Targeting of the RSV Polymerase Complex Prof Richard Plemper Georgia State University, Atlanta, USA	
0930 - 0945	A Phase 3 Pivotal Study of Efficacy and Safety of Oral Ziresovir in RSV-Infected Hospitalized Infants Jim Wu Shanghai Ark Biopharmaceutical, China	[ARNI0072]
0945 - 1000	EDP-323, a Novel L-Protein Inhibitor, for the Treatment of Respiratory Syncytial Virus Micheal Rhodin Enanta Pharmaceuticals, MA, USA	[ARNI0028]
1000 - 1015	Immunomodulation Strategy Against Respiratory Syncytial Virus Infection by Using Lung Primo-colonizing Bacteria Claire Chottin INRAE, France	[ARNI0242]

1015 - 1030	Repurposing Screen Identifies Ionafarnib as RSV Fusion Protein Inhibitor Xiaoyu Zhang Institute for Experimental Virology, Twincore, Hannover, Germany [ARNI0122]
1030 - 1100	Refreshment break - Posters
1100 - 1230	SESSION 7 – RSV Pathogenesis and Immunity in Humans Chairs: Prof. Peter Openshaw, Imperial College London, UK Dr. Gina Aloisio, Baylor College of Medicine, USA
1100 – 1130	Keynote: Older Age and its Impact on Infection in Adults after Human RSV Challenge Prof Chris Chiu Imperial College London, UK
1130 - 1145	Severity-Associated Transcriptional Signatures in the Respiratory Mucosa during Human Paediatric RSV Infection Megan Barnes Imperial College London, UK [ARNI0087]
1145 - 1200	Assessment of Pediatric Lung Respiratory Syncytial Virus Infection at the Single Cell Level Thomas Mariani University of Rochester, NY, USA [ARNI0178]
1200 - 1215	Differential Responses of Paediatric Airway Epithelium from Wheezers and Non-Wheezers to RSV and/or Aeroallergens Sheerian Manzoor Queen’s University Belfast, UK [ARNI0084]
1215 - 1230	Sex-Dependent Enhancement of Respiratory Syncytial Virus Infection by Toll-Like Receptor 7 Ryley McClelland University of Alberta, Canada [ARNI0190]
1230 - 1430	Lunch
1300 - 1400	Industry symposium sponsored by GlaxoSmithKline Biologicals SA Gaining clarity: The Factors that Increase Risk of Viral Respiratory Disease in Adults 1300-1305 Welcome & Introductions – Peter Openshaw Imperial College London, UK 1305-1315 Burden of Respiratory Disease in High-Risk Adult Populations Ann Falsey University of Rochester School of Medicine, New York, USA 1315-1330 Immune Mechanisms Underlying Risk of Infectious Disease in Adults Steven Varga University of Iowa, Iowa City, USA 1330-1345 Respiratory Disease Pathogenesis in Adults Peter Openshaw Imperial College London, UK 1345-1355 Audience Q&A – all speakers 1355-1400 Closing remarks - Peter Openshaw Imperial College London, UK

1430 - 1630	SESSION 8 – RSV Co-infections with Other Viruses and/or Bacteria Chairs: Prof. Janet Englund, University of Washington Seattle Children's Hospital, USA Dr. Lien Ahn Ha Do, Murdoch Children's Research Institute, Australia	
1430 - 1500	Keynote: RSV Co-Infections: Traditional vs. Newer Platforms for Detection of Pathogens Dr Natasha Halasa Vanderbilt University Medical Center, USA	
1500 - 1515	In Vitro Coinfection by Respiratory Syncytial Virus and Influenza A Virus Generates Hybrid Virions with Altered Structure and Tropism Joanne Haney MRC-University of Glasgow Centre for Virus Research, UK	[ARNI0248]
1515 - 1530	Streptococcus Pneumoniae Carriage Density and Associated Respiratory Virus Coinfections in a Congregate Shelter Population in King County, WA Julia Rogers University of Washington, USA	[ARNI0189]
1530 - 1545	Viral Infections and Co-infections Among American Indian and Alaska Native Children with Acute Respiratory Illness, 2019-2022 Rachel Hartman Johns Hopkins University, USA	[ARNI0232]
1545 - 1600	Strong Remodeling of RSV-induced Transcriptional Signature in the Early Stages of Bacterial Superinfection in Human Airway Epithelium Justine Oliva CIRI (Centre International de Recherche en Infectiologie), France	[ARNI0135]
1600 - 1630	Refreshment break Posters	
1630 - 1730	Chanock Lecture – Prof. Larry Anderson, Emory University, USA RSV Then, Now and Tomorrow, One View	
1730 - 1815	Free time	
1815 - 1830	<i>Bus transportation from ICC to Conference Social Event</i>	
1830 - late	Gala Evening at the Titanic Centre Titanic Centre Tour, Wine Reception & Gala Dinner	End of Day 3

0930 - 1100

SESSION 9 – HMPV and Other Respiratory Viruses

Chairs: Prof. Ann Falsey, University of Rochester Medical Center, USA
 Dr. Iebe Rossey, VIB-UGent, Belgium

0930 - 1000

Human Metapneumovirus Replication and Spread

Keynote: Prof. Rebecca Dutch | University of Kentucky College of Medicine, USA

1000 - 1015

Human Metapneumovirus Lacking M2-2 Protein Expression Accumulates Defective Interfering Particles and Hypermutated Genomes that Induce Type-I Interferon Production upon Infection
 Kevin Groen | Erasmus MC, Netherlands [ARNI0180]

1015 - 1030

Investigating The Role of HIF-1a in hMPV and RSV Infections
 Dorothea Morris | University of Texas Medical Branch, USA [ARNI0048]

1030 - 1045

Cross-Protective Antibodies Against Common Endemic Respiratory Viruses
 Jim Boonyaratanakornkit | Fred Hutchinson Cancer Center, WA, USA [ARNI0096]

1045 - 1100

Immunocompromised Cotton Rat Model of Human Metapneumovirus (hMPV) Infection
 Marina Boukhvalova | Sigmovir Biosystems, Inc., USA [ARNI0174]

1100 – 1130

Refreshment break | Posters

1130 - 1300

SESSION 10 – Big Data and RSV

Chairs: Prof. Rosalind Smyth, UCL GOS Institute of Child Health, UK
 Dr. Helen Groves, Queen's University Belfast, UK

1130 - 1200

Using Data to Guide Policy – From Community Transmission to Vaccine Implementation

Keynote: Prof. Cheryl Cohen | University of Witwatersrand & Co-head NICD, S. Africa

1200 - 1215

Examining the Relationship Between Respiratory Syncytial Virus, Influenza, and Rotavirus Seasons' Timing and Severity, and Infant Age at Viral Seasons' Peaks, with Subsequent Childhood Asthma
 Michelle Dimitris | Children's Hospital of Eastern Ontario, Canada [ARNI0056]

1215 - 1230

A Large-Scale Multi-National Prospective Observational Cohort Study Documenting the Summer 2021 RSV Epidemic in the United Kingdom and Ireland
 Thomas Williams | University of Edinburgh, UK [ARNI0059]

Machine Learning in Asthma: Uncovering the Link with RSV Bronchiolitis

Keynote: Prof. Adnan Custovic | Imperial College London, UK

1300 - 1500

Lunch

<p>1330 - 1430</p>	<p>Industry symposium sponsored by AstraZeneca Understanding the Heritage of RSV Immunoprophylaxis to Inform the Care of Our Vulnerable Patients Prof. Sánchez Luna Paediatrics Dept., Hospital General Universitario 'Gregorio Marañón' & Medical Director Neonatology Division NICU</p> <p>1330-1410 Presentation overview:</p> <ul style="list-style-type: none"> • Current status of RSV infection, epidemiology and unmet needs • Long-term sequelae of early lung insults • Current management guidelines and recommendations for the prevention of RSV infections • The concept of RSV immunoprophylaxis - recommended approach for prevention and treatment of RSV-related clinical outcomes <p>1410-1430</p> <ul style="list-style-type: none"> • Q&A session
--------------------	--

<p>1500 - 1630</p>	<p>SESSION 11 – The BIG DEBATE</p> <p><i>Limited understanding of RSV pathogenesis in relevant human populations remains a major block to developing effective RSV vaccines and antivirals</i></p> <p>Panel members:</p> <p><i>For the motion</i> – Professor Peter Openshaw & Professor Janet Englund <i>Against the motion</i> – Professor David Marchant & Dr Christian Felter</p>
<p>1630 -></p>	<p>Closing Remarks</p>

End of Day 4